Skip to content

Point-of-care Assessment of Thrombin Generation and Platelet Function in Children Requiring Cardiopulmonary Bypass

Point-of-care Assessment of Thrombin Generation and Platelet Function in Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02833025
Enrollment
130
Registered
2016-07-14
Start date
2018-12-01
Completion date
2020-12-01
Last updated
2018-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative Coagulopathy, Platelet Function Tests, Thrombin Generation Tests

Brief summary

Coagulopathy after cardiopulmonary bypass (CPB) is associated with increased morbidity and mortality. Clot formation and clot stability are important factors in coagulation and hemostasis. As such platelet dysfunction and impaired thrombin generation play a central role in bleeding after cardiac surgery. The primary objective of this study is to evaluate the relationship between point-of-care determined platelet function and thrombin generation and postoperative bleeding in infants and young children undergoing cardiac surgery with cardiopulmonary bypass adjusting for clinically important confounding factors.

Interventions

DEVICEThrombin generation and Platelet Function Testing

Point-of-care testing of thrombin generation, platelet function, and rotational thromboelastometry

Sponsors

Synapse B.V. Research Institute, University of Maastricht
CollaboratorUNKNOWN
The Hospital for Sick Children
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 5 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≤5 years 2. Undergoing cardiac surgery with cardiopulmonary bypass

Exclusion criteria

1. Non-english speaking parents/care-givers 2. Refusal to consent 3. Extracorporeal membrane oxygenation (ECMO) or ventricular assist device prior to surgery 4. Therapeutic heparin use (unfractionated or low molecular weight) in the immediate preoperative period (\<12 hr) 5. Weight \<3 kg

Design outcomes

Primary

MeasureTime frame
Postoperative chest tube blood loss24hr

Secondary

MeasureTime frameDescription
Transfusion of blood products24hr
All-cause mortalitywithin 30 days
Length of hospital staythrough study completion, an average of less than one month
Postoperative chest tube blood loss6hr
Duration of mechanical ventilationwithin 30 days
Inotropeswithin 30 daysDuration of inotropic support
Kidney injurywithin 30 daysAcute kidney injury
Length of ICU staywithin 30 days

Countries

Canada

Contacts

Primary ContactJames D O'Leary
james.oleary@sickkids.ca416-813-7654

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026